CCM
HZNP

CTC Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CTC Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$765K Buy
7,010
+3,605
+106% +$398K 1.6% 22
2022
Q4 		$387K Buy
+3,405
New +$283K 0.45% 54

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CTC Capital Management's HZNP Position: Q1 2023 in Review

CTC Capital Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 106% in Q1 2023, buying an estimated $398K and bringing the position to 7,010 shares worth $765K. The position accounts for 1.6% of the portfolio, ranked #22.

CTC Capital Management first reported a position in HZNP in Q4 2022 and has held it in 2 quarters since. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • CTC Capital Management held 7,010 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $765K as of Q1 2023.
  • CTC Capital Management bought 3,605 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $398K.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 1.6% of CTC Capital Management's portfolio in Q1 2023, its #22 holding.
  • CTC Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and has held it in 2 quarters since.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.